ANIP
Ani Pharmaceuticals IncCompany with tickers: ANIP
CIK
1023024
CUSIP
00182C103
Shares Outstanding
22,734,618
13F Activity (30d)
176 filings
171 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $237,462,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $10,600,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $38,888,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $29,492,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $1.31 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $1.28 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |